Semaglutide: what it does, how it is titrated, and what to watch

A GLP-1 receptor agonist engineered to survive for a week in a body that clears the natural hormone in minutes. What that engineering did, what the trials measured, and the two things worth monitoring that are not the number on the scale.

A hormone with its half-life problem solved

Native glucagon-like peptide-1 is released from the gut after a meal, and it is destroyed almost immediately — the enzyme DPP-4 dismantles it within about two minutes. Semaglutide is that hormone with three changes: a substitution at position 8 that DPP-4 cannot cut, a fatty-acid side chain that binds it tightly to circulating albumin, and a linker holding the two together. The albumin binding is the important one. Bound drug is not filtered by the kidney and is not available for degradation, so it acts as a reservoir that releases slowly.

Established clinical use The result is a molecule with a roughly one-week half-life doing the job of one with a two-minute half-life. Its effects are the natural hormone's, amplified and sustained: it slows gastric emptying, increases glucose-dependent insulin secretion, suppresses glucagon, and acts on hypothalamic circuits that regulate appetite and food reward. The appetite effect is central rather than gastric, which is why it does not simply feel like a full stomach.

What the trials actually measured

Established clinical use In the STEP 1 trial, published in 2021, adults without diabetes taking 2.4 mg weekly alongside lifestyle intervention lost about 15% of body weight over 68 weeks against roughly 2.4% on placebo. In SELECT, published in 2023, adults with established cardiovascular disease and overweight or obesity but without diabetes had roughly a 20% relative reduction in major adverse cardiovascular events. SELECT is the more consequential of the two, because it measured events rather than a surrogate.

Two caveats travel with those numbers and rarely travel with the headlines. Both are averages across a distribution that includes people who lost very little. And both were measured on continued treatment: STEP 4 examined what happens after withdrawal and found that most of the lost weight returns over the following year. Framing the drug as a course of treatment with an end date is not what the evidence supports; framing it as ongoing is.

Off-label or community practice The muscle question is genuine and under-discussed. Weight lost on any large caloric deficit includes lean mass, and the trials measured weight rather than composition in most cases. This is the basis for the widespread practice of pairing GLP-1 treatment with resistance training and adequate protein, which is sensible and not the same thing as proven — the evidence for it is inference from body-composition principles rather than a trial of the combination.

Why titration is in four-week steps

The titration schedule is not caution for its own sake; it is pharmacokinetics. At a one-week half-life the level roughly doubles from the first dose to steady state, and it takes about five weeks to get there. A step taken sooner than that raises the amount before the previous step has finished arriving, which is how people end up with nausea they attribute to the new amount when it was the old one still accumulating.

Gastrointestinal effects — nausea, vomiting, diarrhoea, constipation — are the dominant adverse effects and are worst during titration steps. They are usually transient. Slower titration is the standard response, and stepping back down is a normal part of the process rather than a failure of it. Anything severe, persistent, or accompanied by significant abdominal pain is a reason to contact the prescriber rather than to wait it out.

The curve, the accumulation ratio and the peak-to-trough figures have a page of their own: Semaglutide half-life and steady state.

The dosing rows the app records

Established clinical use Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Semaglutide, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Hematocrit on testosterone therapy
• HbA1c and fasting glucose

Drawbacks and risks the app records

From the app's own entry. Worth reading alongside the trial results above rather than after them: the same trials that produced the efficacy figures are where most of these came from.

• Nausea, vomiting, diarrhea during titration
• Muscle mass loss without resistance training
• Slow titration required — 4-week increments
• Pancreatitis risk (rare)
• Rebound weight gain upon discontinuation
• Expensive without insurance coverage

Interaction rules that name Semaglutide

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

How long does it take to leave the system after stopping?

At a one-week half-life, most of a dose is gone in about five weeks and effectively all of it in six or seven. Appetite returns over that period rather than the day after the last injection, which is why people describe the change as gradual. The half-life page has the curve.

Is compounded semaglutide the same drug?

It is not the same product, and this page will not tell you it is. A compounded preparation has not been through the manufacturing and testing that produced the approved product, and identity, purity and concentration are only as good as the compounder's own controls. This site names no pharmacy, vendor or testing service, and whether a compounded preparation is appropriate is a question for a prescriber, not a page.

What does the monitoring panel actually look for?

Glycaemic markers to see whether the metabolic effect is happening, lipids because they usually improve, and amylase or lipase only if there is abdominal pain suggesting pancreatitis. Weight and, ideally, some measure of body composition, because weight alone cannot tell you what was lost. The app's own panel for this compound is in the monitoring section above.

Does it interact with testosterone therapy?

The app records a rule about the combination, and it is in the interactions section on this page. The concern is not a pharmacological interaction between the two drugs but the muscle-preservation question above. Whether any combination applies to a particular person is a prescribing decision.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.